Cooperative group research efforts in thoracic malignancies 2009: A review from the 10th annual international lung cancer congress

Clinical Lung Cancer

Volumn 10, Issue 6, 2009, Pages 395-404

  Wakelee, Heather ^a   Loo, Bill W ^a   Kernstine, Kemp H ^b   Putnam, Joe Bill ^c   Edelman, Martin J ^d   Vokes, Everett E ^e   Schiller, Joan H ^f   Baas, Paul ^g   Saijo, Nagahiro ^h   Adjei, Alex ⁱ   Goss, Glenwood ^j   Choy, Hak ^k   Gandara, David R ^l  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j OTTAWA REGIONAL CANCER CENTRE   (Canada)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Bevacizumab; Cediranib; Cetuximab; EGFR mutational status; Mesothelioma; Sunitinib; Vinorelbine

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IMC A12; IRINOTECAN; NAVELBINE; NOGITECAN; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SELENIUM; SUNITINIB; TECHNETIUM SULFUR COLLOID TC 99M; THALIDOMIDE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ZILEUTON;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; MESOTHELIOMA; RADIOFREQUENCY ABLATION; REVIEW; THORAX TUMOR; ARTICLE; CANCER STAGING; COOPERATION; DRUG DELIVERY SYSTEM; LUNG TUMOR; METHODOLOGY; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM STAGING; RESEARCH DESIGN; SMALL CELL LUNG CARCINOMA;

EID: 74949117651     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.075     Document Type: Review

References (41)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353
3. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:277S-89S.
4. Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline. J Clin Oncol 2007; 25:5506-5518
5. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf, Accessed: November 24, 2007.
6. Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4:548-582
7. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a metaanalysis. JAMA 2004; 292:470-484
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550 (Pubitemid 44917502)
9. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132
11. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597 (Pubitemid 41007845)
12. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
13. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009; 27(15 suppl):411s (Abstract 8016).
14. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update on Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006; 24(18 suppl):365s (Abstract 7007).
15. Strauss GM, Herndon J, Maddaus MA, et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004; 22(14 suppl):621s (Abstract 7019).
16. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043-5051
17. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60:615-22, discussion 622-623
18. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355:570-580 (Pubitemid 44200650)
19. Govindan R, Bogart J, Wang X, et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009; 27(15 suppl):383s (Abstract 7505).
20. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy- Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008; 26:848-855
21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899
22. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650-656
23. Schiller JH, Dahlberg SE, Mehta M, et al. A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. J Clin Oncol 2009; 27(15 suppl):382s (Abstract 7503).
24. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-598
25. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15 suppl):407s (Abstract CRA8000).
26. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-smallcell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007; 99:838-846
27. Douillard JY, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol 2005; 23(16 suppl):624s (Abstract 7013).
28. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24:2998-3006.
29. Van Schil PE, Baas P, Gaafar R, et al. Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). J Clin Oncol 2009; 27(15 suppl):384s (Abstract 7509).
30. Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 2004; 22(14 suppl):617s (Abstract 7002).
31. Satouchi M, Yamamoto N, Chiba Y, et al. Randomized phase III study of mitomycin/ vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (NSCLC): WJTOG0105. J Clin Oncol 2009; 27(15 suppl):383s (Abstract 7504).
32. Vincent MD, Butts C, Seymour L, et al. Updated survival analysis of JBR.10: a randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15 suppl):382s (Abstract 7501).
33. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537
34. Kelly K, Gaspar LE, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol 2005; 23(16 suppl):634s (Abstract 7058).
35. Gore EM, Bae K, Wong S, et al. A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: initial analysis of Radiation Therapy Oncology Group 0214. J Clin Oncol 2009; 27(15 suppl):383s (Abstract 7506).
36. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-808
37. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-2291
38. Gandara D, Kim ES, Herbst RS, et al. S0536: carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): a SWOG phase II study. J Clin Oncol 2009; 27(15 suppl):410s (Abstract 8015).
39. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-3357
40. Davies AM, Ho C, Beckett L, et al. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 2009; 4:862-868
41. Garland LL, Chansky K, Wozniak A, et al. SWOG S0509: a phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 2009; 27(15 suppl):384s (Abstract 7511).